[
  {
    "ts": null,
    "headline": "4 Dividend Stocks to Double Up on Right Now",
    "summary": "Plenty of high-performing growth stocks pay dividends -- such as Apple and Nvidia -- and though their dividend yields can be low sometimes, they can also be fast-growing.  When you factor growing dividends into the total returns of slower-growing blue chip companies, they become much more compelling.",
    "url": "https://finnhub.io/api/news?id=fec139a025589cddf9e205260d5fb23546552f9700d61cef7525dc1883ab6c85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735139700,
      "headline": "4 Dividend Stocks to Double Up on Right Now",
      "id": 132161327,
      "image": "https://g.foolcdn.com/editorial/images/801804/getty-happy-person-in-sunglasses-smiling.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Plenty of high-performing growth stocks pay dividends -- such as Apple and Nvidia -- and though their dividend yields can be low sometimes, they can also be fast-growing.  When you factor growing dividends into the total returns of slower-growing blue chip companies, they become much more compelling.",
      "url": "https://finnhub.io/api/news?id=fec139a025589cddf9e205260d5fb23546552f9700d61cef7525dc1883ab6c85"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Why I'm Staying On The Sidelines",
    "summary": "Pfizer trades at a 21.7% discount to peers on a 1-yr forward P/E basis, which is a point for the bullish arguments. Find out why I am neutral on PFE stock.",
    "url": "https://finnhub.io/api/news?id=1372102bad027911555a4cd7ba1eaec1f8eeaa6f3d573ad9f319b1ccc3eeb6f0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735138800,
      "headline": "Pfizer: Why I'm Staying On The Sidelines",
      "id": 132151518,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2152316211/image_2152316211.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer trades at a 21.7% discount to peers on a 1-yr forward P/E basis, which is a point for the bullish arguments. Find out why I am neutral on PFE stock.",
      "url": "https://finnhub.io/api/news?id=1372102bad027911555a4cd7ba1eaec1f8eeaa6f3d573ad9f319b1ccc3eeb6f0"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Inc. (PFE) the Best Dividend Stock to Buy Under $50?",
    "summary": "We recently compiled a list of the 13 Best Dividend Stocks to Buy Under $50. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other dividend stocks. AI stocks are stealing the spotlight today as the appetite for these services continues to gain traction globally. This surge […]",
    "url": "https://finnhub.io/api/news?id=26846d8caecd0efb3a3361b224cf0c6399df3a5e3bb07d0fae996cf38954b313",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735136274,
      "headline": "Is Pfizer Inc. (PFE) the Best Dividend Stock to Buy Under $50?",
      "id": 132161331,
      "image": "https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 13 Best Dividend Stocks to Buy Under $50. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other dividend stocks. AI stocks are stealing the spotlight today as the appetite for these services continues to gain traction globally. This surge […]",
      "url": "https://finnhub.io/api/news?id=26846d8caecd0efb3a3361b224cf0c6399df3a5e3bb07d0fae996cf38954b313"
    }
  },
  {
    "ts": null,
    "headline": "Better Income Stock: Pfizer or Altria Group?",
    "summary": "High-yield dividend stocks often catch investors' attention -- and for good reason.  When established companies maintain larger-than-average dividend payments, they can provide both substantial current income and the potential for long-term appreciation.  Other times, they signal legitimate concerns about a company's ability to maintain its dividend payments in the face of deteriorating business conditions.",
    "url": "https://finnhub.io/api/news?id=dfaa369d90c45a51465d1924f3206e570a03b34ea074ed98d519bf637e38274e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735134300,
      "headline": "Better Income Stock: Pfizer or Altria Group?",
      "id": 132161332,
      "image": "https://g.foolcdn.com/editorial/images/802073/dividends-alternative.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "High-yield dividend stocks often catch investors' attention -- and for good reason.  When established companies maintain larger-than-average dividend payments, they can provide both substantial current income and the potential for long-term appreciation.  Other times, they signal legitimate concerns about a company's ability to maintain its dividend payments in the face of deteriorating business conditions.",
      "url": "https://finnhub.io/api/news?id=dfaa369d90c45a51465d1924f3206e570a03b34ea074ed98d519bf637e38274e"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer (NYSE:PFE) A Risky Investment?",
    "summary": "Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...",
    "url": "https://finnhub.io/api/news?id=5eeb28ee6ec810a729b73a3ac692e45122c835f8649bd198e1a80cf6dc098e11",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735128016,
      "headline": "Is Pfizer (NYSE:PFE) A Risky Investment?",
      "id": 132161333,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8f018d189c2c443014c49845310ae091",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...",
      "url": "https://finnhub.io/api/news?id=5eeb28ee6ec810a729b73a3ac692e45122c835f8649bd198e1a80cf6dc098e11"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst",
    "summary": "Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets cut its price target on the pharmaceutical company from $156 to $105 per share. \"This was supposed to be Novo's answer to Tirzepatide and Retatrutide, some higher efficacy drugs, and it kind of feels like where no man's land here. So we're really focused on next year when it comes to 4Q results, that's going to set the tone for the commercial side of these products for both Lilly and Novo,\" BMO Capital Markets managing director of biopharma equity research Evan Seigerman explains. \"And then mid-year for Lilly, we have Orforglipron, which is their small molecule pill GLP-1, which could really open up the market. So I feel like Novo is kind of losing its pep a little bit,\" he goes on to say to Brad Smith and Josh Lipton. Seigerman — who maintains an Outperform rating Novo Nordisk — also comments on the impact the incoming Trump administration could have on the pharma space, particularly with Robert F. Kennedy Jr. assuming the role of secretary of the Department of Health and Human Services (HHS): \"I think the first thing he could do would be make it more challenging for Medicare to cover GLP-1s for things like heart disease and sleep apnea. That's a big hypothetical...\" To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.",
    "url": "https://finnhub.io/api/news?id=dc451877af6528648c9f98a400db1211a380257b2ab5b236d5154b20ce503913",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735126214,
      "headline": "Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst",
      "id": 132142968,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets cut its price target on the pharmaceutical company from $156 to $105 per share. \"This was supposed to be Novo's answer to Tirzepatide and Retatrutide, some higher efficacy drugs, and it kind of feels like where no man's land here. So we're really focused on next year when it comes to 4Q results, that's going to set the tone for the commercial side of these products for both Lilly and Novo,\" BMO Capital Markets managing director of biopharma equity research Evan Seigerman explains. \"And then mid-year for Lilly, we have Orforglipron, which is their small molecule pill GLP-1, which could really open up the market. So I feel like Novo is kind of losing its pep a little bit,\" he goes on to say to Brad Smith and Josh Lipton. Seigerman — who maintains an Outperform rating Novo Nordisk — also comments on the impact the incoming Trump administration could have on the pharma space, particularly with Robert F. Kennedy Jr. assuming the role of secretary of the Department of Health and Human Services (HHS): \"I think the first thing he could do would be make it more challenging for Medicare to cover GLP-1s for things like heart disease and sleep apnea. That's a big hypothetical...\" To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.",
      "url": "https://finnhub.io/api/news?id=dc451877af6528648c9f98a400db1211a380257b2ab5b236d5154b20ce503913"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth: Don't Let The Market Fool You",
    "summary": "UnitedHealth Group stock, the healthcare sector leader, took a significant hammering as panic sellers bailed out. See why I maintain a buy rating on UNH stock.",
    "url": "https://finnhub.io/api/news?id=9e818cf6b5ac073955196882dd04c6d66cb057e9103b7ac5dd8417e3c16bf42b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735115400,
      "headline": "UnitedHealth: Don't Let The Market Fool You",
      "id": 132143906,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1308861166/image_1308861166.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "UnitedHealth Group stock, the healthcare sector leader, took a significant hammering as panic sellers bailed out. See why I maintain a buy rating on UNH stock.",
      "url": "https://finnhub.io/api/news?id=9e818cf6b5ac073955196882dd04c6d66cb057e9103b7ac5dd8417e3c16bf42b"
    }
  },
  {
    "ts": null,
    "headline": "The Big Companies Funding Trump’s Inauguration Despite Denouncing Jan. 6",
    "summary": "Now, many of those companies are lining up to fund  Donald Trump’s  inauguration.  The Wall Street Journal has identified at least 11 companies and trade associations that are backing the inauguration, which is on track to be the most lucrative ever, after earlier pledging to suspend or reconsider political-action committee donations after Jan. 6.  Ford,  Intuit Toyota  and the Pharmaceutical Research and Manufacturers of America are each giving $1 million.",
    "url": "https://finnhub.io/api/news?id=2700ac93f946aa376f045caca3020d42bef82c43aabb16b9dad24436bd8c7ef5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735092000,
      "headline": "The Big Companies Funding Trump’s Inauguration Despite Denouncing Jan. 6",
      "id": 132139241,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Now, many of those companies are lining up to fund  Donald Trump’s  inauguration.  The Wall Street Journal has identified at least 11 companies and trade associations that are backing the inauguration, which is on track to be the most lucrative ever, after earlier pledging to suspend or reconsider political-action committee donations after Jan. 6.  Ford,  Intuit Toyota  and the Pharmaceutical Research and Manufacturers of America are each giving $1 million.",
      "url": "https://finnhub.io/api/news?id=2700ac93f946aa376f045caca3020d42bef82c43aabb16b9dad24436bd8c7ef5"
    }
  }
]